Page last updated: 2024-12-08
jacobine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
jacobine: RN given refers to (15alpha,20S)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 442741 |
| CHEBI ID | 6080 |
| MeSH ID | M0061443 |
Synonyms (27)
| Synonym |
|---|
| nsc-89936 |
| 12beta-hydroxy-12alpha,13beta-dimethylsenec-1-enine-15s-spiro-2'-(3'r-methyloxiran) |
| senecionan-11,16-dione, 15,20-epoxy-15,20-dihydro-12-hydroxy-, (15-alpha,20s)- |
| 15,20-epoxy-15,20-dihydro-12-hydroxysenecionan-11,16-dione |
| hsdb 3500 |
| (15alpha,20r)15,20-epoxy-15,20-dihydro-12-hydroxy-senecionan-11,16-dione |
| ccris 5777 |
| nsc 89936 |
| senecionan-11,16-dione, 15,20-epoxy-15,20-dihydro-12-hydroxy-, (15alpha,20r)- |
| (15alpha,20r)15,20-epoxy-15,20-dihydro-12-hydroxysenecionan-11,16-dione |
| brn 0054580 |
| jacobine |
| unii-gm32u80h1r |
| gm32u80h1r , |
| 4-27-00-06827 (beilstein handbook reference) |
| jacobine. |
| CHEBI:6080 |
| AKOS027326873 |
| 471-14-7 |
| senecionan-11,16-dione, 15,20-epoxy-15,20-dihydro-12-hydroxy-, (15.alpha.,20s)- |
| jacobine [iarc] |
| spiro((1,6)dioxacyclododecino(2,3,4-gh)pyrrolizine-3(2h),2'-oxirane)-2,7(4h)-dione, 5,6,9,11,13,14,14a,14b-octahydro-6-hydroxy-3',5,6-trimethyl-, (2's,3's,5r,6r,14ar,14br)- |
| (2s,3s,5'r,6'r,9a1'r,14a'r)-6'-hydroxy-3,5',6'-trimethyl-5',6',9',9a1',11',13',14',14a'-octahydro-2'h-spiro[oxirane-2,3'-[1,6]dioxacyclododecino[2,3,4-gh]pyrrolizine]-2',7'(4'h)-dione |
| Q27107031 |
| DTXSID501020078 |
| CS-0084068 |
| HY-124058 |
Research Excerpts
Overview
Jacobine (JAC) is a pyrolizidine alkaloid (PA) exhibiting adverse hepatic effects similar to those induced by another PA, monocrotaline.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Jacobine (JAC) is a pyrolizidine alkaloid (PA) exhibiting adverse hepatic effects similar to those induced by another PA, monocrotaline (MCT). " | ( Genotoxicity of the pyrrolizidine alkaloid jacobine in rats. Bowden, GT; Buhler, DR; Petry, TW; Sipes, IG; Sipes, KG, 1986) | 1.98 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Jacobine (JAC) is a pyrolizidine alkaloid (PA) exhibiting adverse hepatic effects similar to those induced by another PA, monocrotaline (MCT)." | ( Genotoxicity of the pyrrolizidine alkaloid jacobine in rats. Bowden, GT; Buhler, DR; Petry, TW; Sipes, IG; Sipes, KG, 1986) | 1.98 |
| "Pyrrolizidine alkaloids (PAs) are feeding deterrents and toxic compounds to generalist herbivores." | ( Toxicity of pyrrolizidine alkaloids to Spodoptera exigua using insect cell lines and injection bioassays. Klinkhamer, PG; Leiss, KA; Nuringtyas, TR; van Oers, MM; Verpoorte, R, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| pyrrolizine alkaloid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 62.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (62.35) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||